Product
Trifluridine/Tipiracil
Aliases
FTD/TPI, Lonsurf, S 95005, TAS102, TAS-102 (1 other aliases)
16 clinical trials
18 indications
Indication
CancerIndication
Gastroesophageal adenocarcinomaIndication
Colorectal CancerIndication
Metastatic Colorectal CancerIndication
Colorectal AdenocarcinomaIndication
OesogastricIndication
Rectal CancerIndication
Colorectal Cancer MetastaticIndication
Stomach AdenocarcinomaIndication
Esophageal AdenocarcinomaIndication
Esophageal CancerIndication
CholangiocarcinomaIndication
Gallbladder Cancer Stage III AJCC v7Indication
Gallbladder Cancer, Stage IIIA AJCC v7Indication
Stage IIIB Gallbladder Cancer AJCC v7Indication
Gallbladder CancerIndication
Gallbladder Cancer AJCC v7Indication
NSCLCClinical trial
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-11-23
Clinical trial
An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study)Status: Completed, Estimated PCD: 2022-07-19
Clinical trial
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment EfficacyStatus: Active (not recruiting), Estimated PCD: 2023-11-10
Clinical trial
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/CapecitabineStatus: Terminated, Estimated PCD: 2023-02-13
Clinical trial
A Prospective, Open, Single-center, Single-arm Study to Explore Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of mCRC Patients Who Were Refractory to Second-line and Above Standard Therapy.Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC: A Retrospective Cohort Study Based on Propensity Score MatchingStatus: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Single-arm, Phase II Clinical Trial to Treat Locally Advanced, pMMR Rectal Cancer With Single-agent Trifluridine/Tipiracil Chemotherapy Plus Neoadjuvant Intensity-modulated RadiotherapyStatus: Not yet recruiting, Estimated PCD: 2028-12-31
Clinical trial
A Randomised, Open-label, Multi-centre, Two-arm Phase 3 Study Comparing Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil to Trifluridine/Tipiracil Single Agent With a Safety Lead-In Part in Participants With KRAS/NRAS and BRAF Wild Type Metastatic Colorectal Cancer Previously Treated With Standard Treatment and Anti-EGFR TherapyStatus: Terminated, Estimated PCD: 2023-06-21
Clinical trial
A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer PatientsStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type Metastatic Colorectal Cancer: A Single-center, Prospective Phase Ib/II StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet ChemotherapyStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With Metastatic Colorectal Cancer (REFLECT Study)Status: Not yet recruiting, Estimated PCD: 2027-03-01
Clinical trial
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract CancersStatus: Completed, Estimated PCD: 2018-11-30
Clinical trial
Efficacy and Safety of Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy for Refractory Metastatic Colorectal Cancer: a Retrospective StudyStatus: Completed, Estimated PCD: 2022-10-31
Clinical trial
Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2023-05-31
Clinical trial
A Randomized, Controlled, Multicenter Phase II Trial of Regorafenib Combined With Trifluridine/Tipiracil Versus Regorafenib Monotherapy in Patients With Metastatic Colorectal Cancer Who Failed at Least Two Lines of Systematic TherapyStatus: Recruiting, Estimated PCD: 2025-07-04